Company News


Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company"), through its medical face mask manufacturing subsidiary, Micron Technologies Inc. ("Micron Technologies"), sympathizes with the worldwide wave of the Omicron Covid variant and urges its clients to utilize medical grade face masks in any social settings.

Corporate Video:

https://cdn.shopify.com/s/files/1/0492/9627/7672/files/Micron-Commercial.mp4?v=1641791344

Products

Micron Technologies has been operating at its facility in Delta, British Columbia, since August 2020, where it manufactures medical grade face masks under its Medical Device Establishment License issued by Health Canada. Micron Technologies is also registered with the US Food and Drug Administration. The Company's product line focuses on three key product lines:

  1. three ply medical grade face masks, which conform to ASTM F2100 Medical Grade Level 3 standards;
  1. N95 Model 8800 face masks, which have been approved by Health Canada and the US Food and Drug Administration; and
  1. face mask filters.

Available on Amazon, Shopify, and at Walmart

Micron Technologies' three-ply medical grade face masks and N95 Model 8800 face masks are available for purchase on Amazon, Shopify, and at Walmart. Face masks can also be purchased directly from Micron Technologies at https://micronti.com/pages/micron-video

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, British Columbia. The Company, through its subsidiary Micron Technologies, manufactures medical grade face masks. The Company also has an investment in digital telehealth platform in Kayan Health. Kayan Health is an artificial-intelligence powered health communications platform that allows doctors to communicate with their patients and monitor them remotely. https://kayanhealth.com

Kal Malhi, CEO
604-805-4602
kal@bullruncapital.ca

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109477

News Provided by Newsfile via QuoteMedia

DOCT:CNX
Beyond Medical Technologies

Beyond Medical Technologies


Keep reading... Show less
Beyond Medical Provides Corporate Update

Beyond Medical Provides Corporate Update

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") is pleased to provide a corporate update on its medical face mask manufacturing subsidiary Micron Technologies Inc. ("Micron Technologies").

The Company is reviewing Micron Technologies' medical face mask manufacturing business as many jurisdictions have recently lifted mask mandates and as demand for face masks rapidly declines. The Company is considering operating Micron Technologies' facility at reduced capacity or potentially terminating its mask manufacturing business via a sale of all inventory and equipment related to its mask manufacturing business and to seek new business opportunities.

Keep reading... Show less
Beyond Medical Technologies Announces Marketing Initiatives

Beyond Medical Technologies Announces Marketing Initiatives

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to announce that it has entered into an online marketing agreement ("AGORA Agreement") with AGORA Internet Relations Corp. ("AGORA") and an investor marketing agreement (the "INN Agreement") with Dig Media Inc.® dba as Investing News Network® ("INN").

AGORA Internet Relations Corp.

Keep reading... Show less

Beyond Medical Subsidiary Micron Technologies Achieves "Amazon's Choice" Designation and Begins to Accept Bitcoin Payments for its Made in Canada Face Masks

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies ").

Keep reading... Show less

Beyond Medical Manufactures N95 Medical Face Masks as Third Wave of COVID-19 Surges

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies ").

Keep reading... Show less

Beyond Medical subsidiary Micron Technologies begins Sales of Made in Canada Face Masks to Walmart

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies ").

Keep reading... Show less
Albert Labs

Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101

Albert Labs Appoints Dr Sara Tai as Principal Investigator for upcoming RWE Study on KRN-101

Albert Labs International Corp. ( Albert Labs (CSE: ABRT) (FSE: VB50), the "Company"), an R&D company developing mental health therapeutic medicines, is pleased to announce Dr. Sara Tai Senior Lecturer in Clinical Psychology from Manchester University, as Principal Investigator for its upcoming trial. The trial will evaluate the safety and efficacy of KRN-101, a psilocybin-based medicine, for the treatment of cancer-related distress, an indication thought to affect some 15 million patients in Europe and North America .

Keep reading... Show less
two open palms hold a sphere representing the earth with water in the background

Sustainable Packaging: Increasing Demand for Natural Solutions

We only have one planet — and until recently we've done a poor job taking care of it.

The packaging industry is one of the sectors in which this is most evident. With a projected market size of US$1.13 trillion by 2030, it also represents one of the most significant sources of pollution in the world. Globally, we produce roughly 380 million tons of plastic per year. Single-use items such as grocery bags, bottles and packaging represent around 50 percent of that number.

To put this into context, the plastic waste produced by soft drink companies could cover 83 football fields a day, and the pollution footprint of packaging is at least as bad.

Keep reading... Show less
Billy Goat Brands CEO Tony Harris

Billy Goat Brands CEO Tony Harris: Venture Capital Supporting Sustainability

Billy Goat Brands CEO Tony Harris: Venture Capital Supporting Sustainability youtu.be

Keep reading... Show less
Albert Labs

Albert Labs Granted Health Canada Licence

Albert Labs has been issued a Health Canada License enabling the possession, production, and delivery of psilocybin and other psychoactive controlled substances

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines for mental health treatments, is pleased to report it has been granted a Health Canada License dated 05-05-2022 for its research and production facility in Burnaby, Canada . This approval permits the legal possession, production, assembly, sale, and delivery of psilocybin and other psychoactive controlled substances within the confines of the regulations governing controlled substances.

Keep reading... Show less
Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will present at the May 27 to 29 event: From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine which will be held in Toronto, Canada from May 27 to 29, 2022 .

Keep reading... Show less
Albert Labs

Albert Labs' Pre-Clinical Analytical and Toxicological Research Supports Company's Forthcoming Studies

World-renowned scientists from the University of CESPU Health Sciences Department, Portugal are working in partnership with Albert Labs' expert team to conduct safety and toxicology studies, in preparation for KRN-101's use in Real World Evidence studies.

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to create pharmaceutical quality medicines, based on the mycelia of Psilocybe, today released further details of their ongoing preclinical studies. These are currently being conducted at the University of Health Sciences, CESPU, Portugal . The partnership established between Albert Labs and CESPU, provides Albert Labs with preclinical drug assessment capabilities, both in vivo and in vitro. The current work programme provides essential data on Albert Labs' mycelium-based pharmaceutical products in support of clinical trials due to start later this year. The clinical programme will investigate the potential to treat cancer-related distress, an indication thought to affect approximately 15 million patients worldwide.

Keep reading... Show less

Latest Press Releases

Related News

×